{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,11,4]],"date-time":"2026-11-04T23:52:18Z","timestamp":1793836338907,"version":"4.6.1"},"reference-count":132,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2025,8,1]],"date-time":"2025-08-01T00:00:00Z","timestamp":1754006400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2025,8,1]],"date-time":"2025-08-01T00:00:00Z","timestamp":1754006400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2025,8,1]],"date-time":"2025-08-01T00:00:00Z","timestamp":1754006400000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-017"},{"start":{"date-parts":[[2025,8,1]],"date-time":"2025-08-01T00:00:00Z","timestamp":1754006400000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-037"},{"start":{"date-parts":[[2025,8,1]],"date-time":"2025-08-01T00:00:00Z","timestamp":1754006400000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-012"},{"start":{"date-parts":[[2025,8,1]],"date-time":"2025-08-01T00:00:00Z","timestamp":1754006400000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-029"},{"start":{"date-parts":[[2025,8,1]],"date-time":"2025-08-01T00:00:00Z","timestamp":1754006400000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-004"}],"funder":[{"DOI":"10.13039\/501100001809","name":"National Natural Science Foundation of China","doi-asserted-by":"publisher","award":["82260043"],"award-info":[{"award-number":["82260043"]}],"id":[{"id":"10.13039\/501100001809","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100004479","name":"Jiangxi Provincial Natural Science Foundation","doi-asserted-by":"publisher","award":["20232ACB206016"],"award-info":[{"award-number":["20232ACB206016"]}],"id":[{"id":"10.13039\/501100004479","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100004479","name":"Jiangxi Provincial Natural Science Foundation","doi-asserted-by":"publisher","award":["20204BCJ22030"],"award-info":[{"award-number":["20204BCJ22030"]}],"id":[{"id":"10.13039\/501100004479","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100014718","name":"Innovative Research Group Project of the National Natural Science Foundation of China","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100014718","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100012259","name":"Major Discipline Academic and Technical Leaders Training Program of Jiangxi Province","doi-asserted-by":"publisher","award":["20225BCJ22001"],"award-info":[{"award-number":["20225BCJ22001"]}],"id":[{"id":"10.13039\/501100012259","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["International Immunopharmacology"],"published-print":{"date-parts":[[2025,8]]},"DOI":"10.1016\/j.intimp.2025.115012","type":"journal-article","created":{"date-parts":[[2025,6,9]],"date-time":"2025-06-09T05:16:22Z","timestamp":1749446182000},"page":"115012","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":3,"special_numbering":"C","title":["Targeting epigenetic reprogramming in DLBCL and its interaction with the tumor microenvironment for novel therapeutic approaches"],"prefix":"10.1016","volume":"161","author":[{"given":"Lili","family":"Zhou","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Wei","family":"Cheng","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Qingqing","family":"Luo","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Chunhong","family":"Huang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Li","family":"Yu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.intimp.2025.115012_bb0005","doi-asserted-by":"crossref","first-page":"41","DOI":"10.1016\/j.ctrv.2018.01.002","article-title":"Targeting the B-cell receptor pathway in diffuse large B-cell lymphoma","volume":"65","author":"Dunleavy","year":"2018","journal-title":"Cancer Treat. Rev."},{"key":"10.1016\/j.intimp.2025.115012_bb0010","article-title":"Diffuse large B-cell lymphoma: from novel molecular classifications to tailored targeted therapies","volume":"8","author":"Lue","year":"2022","journal-title":"Journal of Cancer Metastasis and Treatment"},{"key":"10.1016\/j.intimp.2025.115012_bb0015","first-page":"1","article-title":"Getting the right combination to break the epigenetic code","author":"Tolu","year":"2024","journal-title":"Nat. Rev. Clin. Oncol."},{"key":"10.1016\/j.intimp.2025.115012_bb0020","first-page":"494","article-title":"Emerging epigenetic-modulating therapies in lymphoma, nature reviews","volume":"16","author":"Sermer","year":"2019","journal-title":"Clin. Oncol."},{"key":"10.1016\/j.intimp.2025.115012_bb0025","doi-asserted-by":"crossref","first-page":"380","DOI":"10.1016\/j.ccell.2020.06.002","article-title":"Immunogenomic landscape of hematological malignancies","volume":"38","author":"Dufva","year":"2020","journal-title":"Cancer Cell."},{"key":"10.1016\/j.intimp.2025.115012_bb0030","doi-asserted-by":"crossref","first-page":"1722","DOI":"10.1111\/j.1349-7006.2010.01569.x","article-title":"DNA methyltransferase DNMT3b protein overexpression as a prognostic factor in patients with diffuse large B-cell lymphomas","volume":"101","author":"Amara","year":"2010","journal-title":"Cancer Sci."},{"key":"10.1016\/j.intimp.2025.115012_bb0035","doi-asserted-by":"crossref","first-page":"134","DOI":"10.1016\/j.prp.2017.10.005","article-title":"DNMT1 is associated with cell cycle and DNA replication gene sets in diffuse large B-cell lymphoma","volume":"214","author":"Suet Loo","year":"2018","journal-title":"Pathol. Res. Pract."},{"key":"10.1016\/j.intimp.2025.115012_bb0040","doi-asserted-by":"crossref","first-page":"123","DOI":"10.1038\/s41408-020-00389-w","article-title":"Genetic and epigenetic determinants of diffuse large B-cell lymphoma","volume":"10","author":"Bakhshi","year":"2020","journal-title":"Blood Cancer J."},{"key":"10.1016\/j.intimp.2025.115012_bb0045","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1186\/s13046-024-03235-0","article-title":"Ferroptosis and the tumor microenvironment","volume":"43","author":"Cui","year":"2024","journal-title":"J. Exp. Clin. Cancer Res."},{"key":"10.1016\/j.intimp.2025.115012_bb0050","doi-asserted-by":"crossref","first-page":"134","DOI":"10.1016\/j.ejca.2016.09.010","article-title":"Turning tumour cells into antigen presenting cells: the next step to improve cancer immunotherapy?","volume":"68","author":"Charette","year":"2016","journal-title":"Eur. J. Cancer."},{"key":"10.1016\/j.intimp.2025.115012_bb0055","doi-asserted-by":"crossref","first-page":"1684","DOI":"10.1038\/leu.2015.57","article-title":"IL10 receptor is a novel therapeutic target in DLBCLs","volume":"29","author":"Sawh B\u00e9guelin","year":"2015","journal-title":"Leukemia."},{"key":"10.1016\/j.intimp.2025.115012_bb0060","doi-asserted-by":"crossref","DOI":"10.1016\/j.intimp.2021.107662","article-title":"High levels of Tim-3+Foxp3+Treg cells in the tumor microenvironment is a prognostic indicator of poor survival of diffuse large B cell lymphoma patients","volume":"96","author":"Zhong","year":"2021","journal-title":"Int. Immunopharmacol."},{"key":"10.1016\/j.intimp.2025.115012_bb0065","doi-asserted-by":"crossref","first-page":"835","DOI":"10.3390\/cancers15030835","article-title":"The immunology of DLBCL","volume":"15","author":"Takahara","year":"2023","journal-title":"Cancers"},{"key":"10.1016\/j.intimp.2025.115012_bb0070","doi-asserted-by":"crossref","first-page":"1791","DOI":"10.1016\/S0140-6736(23)02705-8","article-title":"B-cell non-Hodgkin lymphomas","volume":"403","author":"Silkenstedt","year":"2024","journal-title":"Lancet"},{"key":"10.1016\/j.intimp.2025.115012_bb0075","doi-asserted-by":"crossref","first-page":"481","DOI":"10.1016\/j.cell.2017.09.027","article-title":"Genetic and functional drivers of diffuse large B cell lymphoma","volume":"171","author":"Reddy","year":"2017","journal-title":"Cell"},{"key":"10.1016\/j.intimp.2025.115012_bb0080","doi-asserted-by":"crossref","first-page":"10","DOI":"10.1038\/s41392-020-00437-8","article-title":"CREBBP\/EP300 mutations promoted tumor progression in diffuse large B-cell lymphoma through altering tumor-associated macrophage polarization via FBXW7-NOTCH-CCL2\/CSF1 axis","volume":"6","author":"Huang","year":"2021","journal-title":"Signal Transduct. Target. Ther."},{"key":"10.1016\/j.intimp.2025.115012_bb0085","first-page":"107","article-title":"IFNgamma and lymphocytes prevent primary tumour development and shape tumour immunogenicity","volume":"410","author":"Vijay Shankaran","year":"2001","journal-title":"Nature."},{"key":"10.1016\/j.intimp.2025.115012_bb0090","first-page":"59","article-title":"Mechanisms of immune evasion and novel treatments for relapsed and refractory diffuse large B-cell lymphoma, oncology","volume":"2","author":"Kossow","year":"2024","journal-title":"Advances"},{"key":"10.1016\/j.intimp.2025.115012_bb0095","doi-asserted-by":"crossref","first-page":"652","DOI":"10.1038\/89810","article-title":"CIITA coordinates multiple histone acetylation modifications at the HLA-DRA promoter","volume":"2","author":"Beresford","year":"2001","journal-title":"Nat. Immunol."},{"key":"10.1016\/j.intimp.2025.115012_bb0100","doi-asserted-by":"crossref","first-page":"9701","DOI":"10.1073\/pnas.1619555114","article-title":"Inactivation of CREBBP expands the germinal center B cell compartment, down-regulates MHCII expression and promotes DLBCL growth","volume":"114","author":"Hashwah","year":"2017","journal-title":"Proc. Natl. Acad. Sci."},{"key":"10.1016\/j.intimp.2025.115012_bb0105","doi-asserted-by":"crossref","first-page":"3916","DOI":"10.1158\/0008-5472.CAN-18-3622","article-title":"CBP\/p300 drives the differentiation of regulatory T cells through transcriptional and non-transcriptional mechanisms","volume":"79","author":"Castillo","year":"2019","journal-title":"Cancer Res."},{"key":"10.1016\/j.intimp.2025.115012_bb0110","first-page":"1411","article-title":"Histone deacetylase inhibitors enhance CD1d-dependent NKT cell responses to lymphoma, Cancer immunology","volume":"65","author":"Tiper","year":"2016","journal-title":"Immunotherapy"},{"key":"10.1016\/j.intimp.2025.115012_bb0115","doi-asserted-by":"crossref","DOI":"10.1097\/MD.0000000000034577","article-title":"Comprehensive analysis of HDAC7 expression and its prognostic value in diffuse large B cell lymphoma: a review","volume":"102","author":"Lu","year":"2023","journal-title":"Medicine"},{"key":"10.1016\/j.intimp.2025.115012_bb0120","doi-asserted-by":"crossref","first-page":"579","DOI":"10.1016\/j.molimm.2014.08.002","article-title":"Histone deacetylase 11: a novel epigenetic regulator of myeloid derived suppressor cell expansion and function","volume":"63","author":"Sahakian","year":"2015","journal-title":"Mol. Immunol."},{"key":"10.1016\/j.intimp.2025.115012_bb0125","doi-asserted-by":"crossref","first-page":"E2865","DOI":"10.1073\/pnas.1121131109","article-title":"Requirement for the histone deacetylase Hdac3 for the inflammatory gene expression program in macrophages","volume":"109","author":"Chen","year":"2012","journal-title":"Proc. Natl. Acad. Sci."},{"key":"10.1016\/j.intimp.2025.115012_bb0130","doi-asserted-by":"crossref","first-page":"1871","DOI":"10.1161\/ATVBAHA.114.303393","article-title":"Histone deacetylase 9 represses cholesterol efflux and alternatively activated macrophages in atherosclerosis development","volume":"34","author":"Cao","year":"2014","journal-title":"Arterioscler. Thromb. Vasc. Biol."},{"key":"10.1016\/j.intimp.2025.115012_bb0135","doi-asserted-by":"crossref","first-page":"5414","DOI":"10.18632\/oncotarget.14289","article-title":"Lymphocyte-to-monocyte ratio is associated with prognosis of diffuse large B-cell lymphoma: correlation with CD163 positive M2 type tumor-associated macrophages, not PD-1 positive tumor-infiltrating lymphocytes","volume":"8","author":"Wang","year":"2017","journal-title":"Oncotarget"},{"key":"10.1016\/j.intimp.2025.115012_bb0140","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1186\/s12885-019-6208-x","article-title":"Tumor-associated macrophages predict prognosis in diffuse large B-cell lymphoma and correlation with peripheral absolute monocyte count","volume":"19","author":"Li","year":"2019","journal-title":"BMC Cancer"},{"key":"10.1016\/j.intimp.2025.115012_bb0145","doi-asserted-by":"crossref","DOI":"10.1172\/JCI183391","article-title":"Epigenetic therapies targeting histone lysine methylation: complex mechanisms and clinical challenges","volume":"134","author":"Gold","year":"2024","journal-title":"J. Clin. Invest."},{"key":"10.1016\/j.intimp.2025.115012_bb0150","doi-asserted-by":"crossref","first-page":"551","DOI":"10.1016\/j.ccell.2020.03.015","article-title":"A probabilistic classification tool for genetic subtypes of diffuse large B cell lymphoma with therapeutic implications","volume":"37","author":"Wright","year":"2020","journal-title":"Cancer Cell"},{"key":"10.1016\/j.intimp.2025.115012_bb0155","doi-asserted-by":"crossref","first-page":"679","DOI":"10.1038\/s41591-018-0016-8","article-title":"Molecular subtypes of diffuse large B cell lymphoma are associated with distinct pathogenic mechanisms and outcomes","volume":"24","author":"Chapuy","year":"2018","journal-title":"Nat. Med."},{"key":"10.1016\/j.intimp.2025.115012_bb0160","first-page":"1415","article-title":"The complex role of EZH2 in the tumor microenvironment: opportunities and challenges for immunotherapy combinations, future","volume":"12","author":"Qiu","year":"2020","journal-title":"Med. Chem."},{"key":"10.1016\/j.intimp.2025.115012_bb0165","first-page":"CD-18-1090","article-title":"Molecular and genetic characterization of MHC deficiency identifies EZH2 as therapeutic target for enhancing immune recognition, Cancer","volume":"9","author":"Ennishi","year":"2019","journal-title":"Discovery"},{"key":"10.1016\/j.intimp.2025.115012_bb0170","doi-asserted-by":"crossref","first-page":"116","DOI":"10.1016\/j.immuni.2020.11.002","article-title":"Genome-wide screens identify lineage-and tumor-specific genes modulating MHC-I-and MHC-II-restricted immunosurveillance of human lymphomas","volume":"54","author":"Dersh","year":"2021","journal-title":"Immunity"},{"key":"10.1016\/j.intimp.2025.115012_bb0175","doi-asserted-by":"crossref","first-page":"655","DOI":"10.1016\/j.ccell.2020.04.004","article-title":"Mutant EZH2 induces a pre-malignant lymphoma niche by reprogramming the immune response","volume":"37","author":"B\u00e9guelin","year":"2020","journal-title":"Cancer Cell"},{"key":"10.1016\/j.intimp.2025.115012_bb0180","doi-asserted-by":"crossref","first-page":"3452","DOI":"10.1038\/s41467-024-47701-x","article-title":"EZH2 mutations in follicular lymphoma distort H3K27me3 profiles and alter transcriptional responses to PRC2 inhibition","volume":"15","author":"Romero","year":"2024","journal-title":"Nat. Commun."},{"key":"10.1016\/j.intimp.2025.115012_bb0185","doi-asserted-by":"crossref","first-page":"34","DOI":"10.1182\/blood-2020-141168","article-title":"The tumor associated antigen PRAME exhibits dualistic functions that are targetable in diffuse large B-cell lymphoma","volume":"136","author":"Takata","year":"2020","journal-title":"Blood"},{"key":"10.1016\/j.intimp.2025.115012_bb0190","doi-asserted-by":"crossref","first-page":"35","DOI":"10.1016\/j.molimm.2020.01.006","article-title":"EZH2 inhibitors restore epigenetically silenced CD58 expression in B-cell lymphomas","volume":"119","author":"Otsuka","year":"2020","journal-title":"Mol. Immunol."},{"key":"10.1016\/j.intimp.2025.115012_bb0195","doi-asserted-by":"crossref","DOI":"10.1093\/nar\/gkaa317","article-title":"H2B ubiquitylation enhances H3K4 methylation activities of human KMT2 family complexes","volume":"48","author":"Kwon","year":"2020","journal-title":"Nucleic Acids Res."},{"key":"10.1016\/j.intimp.2025.115012_bb0200","doi-asserted-by":"crossref","DOI":"10.3389\/fcell.2021.805195","article-title":"Epigenetic, metabolic, and immune crosstalk in germinal-center-derived B-cell lymphomas: unveiling new vulnerabilities for rational combination therapies","volume":"9","author":"Serganova","year":"2022","journal-title":"Frontiers in Cell and Developmental Biology"},{"key":"10.1016\/j.intimp.2025.115012_bb0205","first-page":"595","article-title":"Chromatin modifying gene mutations in follicular lymphoma, blood, the journal of the American society of","volume":"131","author":"Green","year":"2018","journal-title":"Hematology"},{"key":"10.1016\/j.intimp.2025.115012_bb0210","doi-asserted-by":"crossref","first-page":"1199","DOI":"10.1038\/nm.3943","article-title":"The histone lysine methyltransferase KMT2D sustains a gene expression program that represses B cell lymphoma development","volume":"21","author":"Ortega-Molina","year":"2015","journal-title":"Nat. Med."},{"key":"10.1016\/j.intimp.2025.115012_bb0215","doi-asserted-by":"crossref","first-page":"405","DOI":"10.1016\/j.cell.2016.08.032","article-title":"Loss of the HVEM tumor suppressor in lymphoma and restoration by modified CAR-T cells","volume":"167","author":"Boice","year":"2016","journal-title":"Cell"},{"key":"10.1016\/j.intimp.2025.115012_bb0220","doi-asserted-by":"crossref","first-page":"3972","DOI":"10.7150\/ijbs.93349","article-title":"KMT2D Mutations Promoted Tumor Progression in Diffuse Large B-Cell Lymphoma through Altering Tumor-Induced Regulatory T Cell Trafficking Via FBXW7-NOTCH-MYC\/TGF-\u03b21 axis","volume":"20","author":"Liu","year":"2024","journal-title":"Int. J. Biol. Sci."},{"key":"10.1016\/j.intimp.2025.115012_bb0225","doi-asserted-by":"crossref","first-page":"2879","DOI":"10.1038\/s41467-024-47012-1","article-title":"Loss of CREBBP and KMT2D cooperate to accelerate lymphomagenesis and shape the lymphoma immune microenvironment","volume":"15","author":"Li","year":"2024","journal-title":"Nat. Commun."},{"key":"10.1016\/j.intimp.2025.115012_bb0230","doi-asserted-by":"crossref","first-page":"623","DOI":"10.1038\/s41580-022-00483-w","article-title":"Establishment of H3K9-methylated heterochromatin and its functions in tissue differentiation and maintenance","volume":"23","author":"Padeken","year":"2022","journal-title":"Nat. Rev. Mol. Cell Biol."},{"key":"10.1016\/j.intimp.2025.115012_bb0235","doi-asserted-by":"crossref","first-page":"11466","DOI":"10.3390\/ijms252111466","article-title":"The roles of H3K9me3 writers, readers, and erasers in Cancer immunotherapy","volume":"25","author":"Oleksiewicz","year":"2024","journal-title":"Int. J. Mol. Sci."},{"key":"10.1016\/j.intimp.2025.115012_bb0240","series-title":"Clinical expression and prognosis of SUV39H1 in diffuse large B-cell lymphoma","author":"Zhang","year":"2025"},{"key":"10.1016\/j.intimp.2025.115012_bb0245","doi-asserted-by":"crossref","first-page":"2438","DOI":"10.1007\/s12094-023-03128-2","article-title":"SUV39H1 is a prognosis and immune microenvironment-related biomarker in diffuse large B-cell lymphoma","volume":"25","author":"Zhang","year":"2023","journal-title":"Clin. Transl. Oncol."},{"key":"10.1016\/j.intimp.2025.115012_bb0250","doi-asserted-by":"crossref","first-page":"381","DOI":"10.1038\/s41392-023-01626-x","article-title":"Human endogenous retroviruses as epigenetic therapeutic targets in TP53-mutated diffuse large B-cell lymphoma","volume":"8","author":"Fang","year":"2023","journal-title":"Signal Transduct. Target. Ther."},{"key":"10.1016\/j.intimp.2025.115012_bb0255","doi-asserted-by":"crossref","first-page":"210","DOI":"10.1038\/s41392-023-01480-x","article-title":"Epigenetic regulation in the tumor microenvironment: molecular mechanisms and therapeutic targets","volume":"8","author":"Yang","year":"2023","journal-title":"Signal Transduct. Target. Ther."},{"key":"10.1016\/j.intimp.2025.115012_bb0260","doi-asserted-by":"crossref","first-page":"210","DOI":"10.3389\/fonc.2019.00210","article-title":"TET2 function in hematopoietic malignancies, immune regulation, and DNA repair","volume":"9","author":"Feng","year":"2019","journal-title":"Front. Oncol."},{"key":"10.1016\/j.intimp.2025.115012_bb0265","doi-asserted-by":"crossref","DOI":"10.1002\/ctm2.70066","article-title":"Comprehensive review and updated analysis of DNA methylation in hepatocellular carcinoma: from basic research to clinical application","volume":"14","author":"Su","year":"2024","journal-title":"Clin. Transl. Med."},{"key":"10.1016\/j.intimp.2025.115012_bb0270","doi-asserted-by":"crossref","first-page":"731","DOI":"10.1016\/j.pathol.2017.08.009","article-title":"DNMT1 is predictive of survival and associated with Ki-67 expression in R-CHOP-treated diffuse large B-cell lymphomas","volume":"49","author":"Loo","year":"2017","journal-title":"Pathology"},{"key":"10.1016\/j.intimp.2025.115012_bb0275","doi-asserted-by":"crossref","first-page":"151","DOI":"10.1038\/s41586-020-2747-1","article-title":"Structure of nucleosome-bound DNA methyltransferases DNMT3A and DNMT3B","volume":"586","author":"Xu","year":"2020","journal-title":"Nature"},{"key":"10.1016\/j.intimp.2025.115012_bb0280","doi-asserted-by":"crossref","first-page":"401","DOI":"10.1186\/s13287-024-04008-4","article-title":"Emerging insights into epigenetics and hematopoietic stem cell trafficking in age-related hematological malignancies","volume":"15","author":"Xinyi","year":"2024","journal-title":"Stem Cell Res Ther"},{"key":"10.1016\/j.intimp.2025.115012_bb0285","doi-asserted-by":"crossref","first-page":"249","DOI":"10.1038\/nature15520","article-title":"Epigenetic silencing of TH1-type chemokines shapes tumour immunity and immunotherapy","volume":"527","author":"Peng","year":"2015","journal-title":"Nature"},{"key":"10.1016\/j.intimp.2025.115012_bb0290","doi-asserted-by":"crossref","first-page":"1989790","DOI":"10.1080\/2162402X.2021.1989790","article-title":"DNMT1 constrains IFN\u03b2-mediated anti-tumor immunity and PD-L1 expression to reduce the efficacy of radiotherapy and immunotherapy","volume":"10","author":"Huang","year":"2021","journal-title":"OncoImmunology"},{"key":"10.1016\/j.intimp.2025.115012_bb0295","doi-asserted-by":"crossref","first-page":"142","DOI":"10.1016\/j.neo.2020.01.002","article-title":"AID assists DNMT1 to attenuate BCL6 expression through DNA methylation in diffuse large B-cell lymphoma cell lines","volume":"22","author":"Jiao","year":"2020","journal-title":"Neoplasia"},{"key":"10.1016\/j.intimp.2025.115012_bb0300","doi-asserted-by":"crossref","first-page":"1786","DOI":"10.21037\/tcr-23-1943","article-title":"DNMT3A promotes glioma growth and malignancy via TNF-\u03b1\/NF-\u03baB signaling pathway","volume":"13","author":"Su","year":"2024","journal-title":"Transl. Cancer Res."},{"key":"10.1016\/j.intimp.2025.115012_bb0305","first-page":"1","article-title":"High-plex spatial transcriptomic profiling reveals distinct immune components and the HLA class I\/DNMT3A\/CD8 modulatory axis in mismatch repair-deficient endometrial cancer","author":"Guo","year":"2023","journal-title":"Cell. Oncol."},{"key":"10.1016\/j.intimp.2025.115012_bb0310","doi-asserted-by":"crossref","first-page":"1177590","DOI":"10.3389\/fonc.2023.1177590","article-title":"Angioimmunoblastic T-cell lymphoma and correlated neoplasms with T-cell follicular helper phenotype: from molecular mechanisms to therapeutic advances","volume":"13","author":"Lage","year":"2023","journal-title":"Front. Oncol."},{"key":"10.1016\/j.intimp.2025.115012_bb0315","doi-asserted-by":"crossref","first-page":"2612","DOI":"10.1158\/0008-5472.CAN-19-3339","article-title":"Induction of DNMT3B by PGE2 and IL6 at distant metastatic sites promotes epigenetic modification and breast cancer colonization","volume":"80","author":"So","year":"2020","journal-title":"Cancer Res."},{"key":"10.1016\/j.intimp.2025.115012_bb0320","doi-asserted-by":"crossref","first-page":"565","DOI":"10.1210\/me.2013-1293","article-title":"Epigenetic regulation of macrophage polarization by DNA methyltransferase 3b","volume":"28","author":"Yang","year":"2014","journal-title":"Mol. Endocrinol."},{"key":"10.1016\/j.intimp.2025.115012_bb0325","doi-asserted-by":"crossref","DOI":"10.1182\/blood.2024026020","article-title":"Biology as vulnerability in follicular lymphoma: genetics, epigenetics, and immunogenetics","author":"Araujo-Ayala","year":"2025","journal-title":"Blood J."},{"key":"10.1016\/j.intimp.2025.115012_bb0330","doi-asserted-by":"crossref","first-page":"592","DOI":"10.1038\/ni.3176","article-title":"TET1: an epigenetic guardian of lymphomagenesis","volume":"16","author":"Rasmussen","year":"2015","journal-title":"Nat. Immunol."},{"key":"10.1016\/j.intimp.2025.115012_bb0335","first-page":"8068","article-title":"A circular RNA from APC inhibits the proliferation of diffuse large B-cell lymphoma by inactivating Wnt\/\u03b2-catenin signaling via interacting with TET1 and miR-888","volume":"11","author":"Yanping","year":"2025","journal-title":"Aging"},{"key":"10.1016\/j.intimp.2025.115012_bb0340","doi-asserted-by":"crossref","first-page":"602","DOI":"10.52586\/4970","article-title":"Methylation Alterations and Advance of Treatment in Lymphoma","volume":"26","author":"Liu","year":"2021","journal-title":"Frontiers in Bioscience, Landmark"},{"key":"10.1016\/j.intimp.2025.115012_bb0345","first-page":"1515","article-title":"TET2 deficiency sets the stage for B-cell lymphoma, Cancer","volume":"8","author":"Shingleton","year":"2018","journal-title":"Discovery"},{"key":"10.1016\/j.intimp.2025.115012_bb0350","doi-asserted-by":"crossref","first-page":"eaay5872","DOI":"10.1126\/sciadv.aay5872","article-title":"TET2 deficiency reprograms the germinal center B cell epigenome and silences genes linked to lymphomagenesis","volume":"6","author":"Rosikiewicz","year":"2020","journal-title":"Sci. Adv."},{"key":"10.1016\/j.intimp.2025.115012_bb0355","doi-asserted-by":"crossref","first-page":"3777","DOI":"10.3892\/mmr.2017.7058","article-title":"Integrated analysis of genome-wide gene expression and DNA methylation microarray of diffuse large B-cell lymphoma with TET mutations","volume":"16","author":"Liu","year":"2017","journal-title":"Mol. Med. Rep."},{"key":"10.1016\/j.intimp.2025.115012_bb0360","doi-asserted-by":"crossref","first-page":"274","DOI":"10.2174\/1568009620666210106122750","article-title":"Epigenetic mechanisms of therapy resistance in diffuse large B cell lymphoma (DLBCL)","volume":"21","author":"Isshiki","year":"2021","journal-title":"Curr. Cancer Drug Targets"},{"key":"10.1016\/j.intimp.2025.115012_bb0365","doi-asserted-by":"crossref","first-page":"471","DOI":"10.1016\/j.immuni.2016.09.001","article-title":"Germinal center B cell dynamics","volume":"45","author":"Mesin","year":"2016","journal-title":"Immunity"},{"key":"10.1016\/j.intimp.2025.115012_bb0370","doi-asserted-by":"crossref","first-page":"853","DOI":"10.3390\/biomedicines13040853","article-title":"Epigenetic symphony in diffuse large B-cell lymphoma: orchestrating the tumor microenvironment","volume":"13","author":"Caloian","year":"2025","journal-title":"Biomedicines"},{"key":"10.1016\/j.intimp.2025.115012_bb0375","doi-asserted-by":"crossref","DOI":"10.1158\/2159-8290.CD-18-0657","article-title":"TET2 deficiency causes germinal center hyperplasia, impairs plasma cell differentiation, and promotes B-cell lymphomagenesis","volume":"8","author":"Dominguez","year":"2018","journal-title":"Cancer Discov."},{"key":"10.1016\/j.intimp.2025.115012_bb0380","doi-asserted-by":"crossref","first-page":"99","DOI":"10.1038\/s41590-021-01087-w","article-title":"TET deficiency perturbs mature B cell homeostasis and promotes oncogenesis associated with accumulation of G-quadruplex and R-loop structures","volume":"23","author":"Shukla","year":"2022","journal-title":"Nat. Immunol."},{"key":"10.1016\/j.intimp.2025.115012_bb0385","doi-asserted-by":"crossref","first-page":"785","DOI":"10.1016\/j.immuni.2012.09.010","article-title":"T cell receptor stimulation-induced epigenetic changes and Foxp3 expression are independent and complementary events required for Treg cell development","volume":"37","author":"Ohkura","year":"2012","journal-title":"Immunity"},{"key":"10.1016\/j.intimp.2025.115012_bb0390","doi-asserted-by":"crossref","DOI":"10.3389\/fcell.2021.727935","article-title":"Uncovering the association between m5C regulator-mediated methylation modification patterns and tumour microenvironment infiltration characteristics in hepatocellular carcinoma","volume":"9","author":"Gu","year":"2021","journal-title":"Frontiers in cell and developmental biology"},{"key":"10.1016\/j.intimp.2025.115012_bb0395","article-title":"Prognostic characteristics and immune effects of N6-methyladenosine and 5-Methylcytosine-related regulatory factors in clear cell renal cell carcinoma","volume":"13","author":"Li","year":"2022","journal-title":"Front. Genet."},{"key":"10.1016\/j.intimp.2025.115012_bb0400","article-title":"5-Methylcytosine-related long noncoding RNAs are potential biomarkers to predict overall survival and regulate tumor-immune environment in patients with bladder cancer","volume":"2022","author":"Li","year":"2022","journal-title":"Dis. Markers"},{"key":"10.1016\/j.intimp.2025.115012_bb0405","doi-asserted-by":"crossref","DOI":"10.3389\/fonc.2022.788801","article-title":"NSUN2 promotes tumor progression and regulates immune infiltration in nasopharyngeal carcinoma","volume":"12","author":"Tong","year":"2022","journal-title":"Front. Oncol."},{"key":"10.1016\/j.intimp.2025.115012_bb0410","doi-asserted-by":"crossref","first-page":"1207371","DOI":"10.3389\/fimmu.2023.1207371","article-title":"Vital roles of m5C RNA modification in cancer and immune cell biology","volume":"14","author":"Gu","year":"2023","journal-title":"Front. Immunol."},{"key":"10.1016\/j.intimp.2025.115012_bb0415","doi-asserted-by":"crossref","first-page":"1285","DOI":"10.1158\/0008-5472.CAN-18-2965","article-title":"The critical role of RNA m6A methylation in cancer","volume":"79","author":"Lan","year":"2019","journal-title":"Cancer Res."},{"key":"10.1016\/j.intimp.2025.115012_bb0420","doi-asserted-by":"crossref","DOI":"10.1016\/j.heliyon.2023.e22209","article-title":"Identification and validation of 5-methylcytosine-associated genes in diffuse large B-cell lymphoma","volume":"9","author":"Xing","year":"2023","journal-title":"Heliyon"},{"key":"10.1016\/j.intimp.2025.115012_bb0425","doi-asserted-by":"crossref","first-page":"1768","DOI":"10.62347\/NXDR1826","article-title":"Roles of RNA m5C modification patterns in prognosis and tumor microenvironment infiltration of diffuse large B-cell lymphoma","volume":"14","author":"Cui","year":"2024","journal-title":"Am. J. Cancer Res."},{"key":"10.1016\/j.intimp.2025.115012_bb0430","doi-asserted-by":"crossref","first-page":"6115","DOI":"10.1080\/21655979.2021.1972644","article-title":"Expression of N6-Methyladenosine (m6A) Regulators Correlates with Immune Microenvironment Infiltration and Predicts Prognosis in Diffuse Large Cell Lymphoma (DLBCL)","volume":"12","author":"Xie","year":"2021","journal-title":"Bioengineered"},{"key":"10.1016\/j.intimp.2025.115012_bb0435","doi-asserted-by":"crossref","DOI":"10.26855\/ijcemr.2023.07.022","article-title":"Investigate the function and immune correlation of the methylation modification of m6A regulators in DLBCL","volume":"7","author":"Meng","year":"2023","journal-title":"International Journal of Clinical and Experimental Medicine Research"},{"key":"10.1016\/j.intimp.2025.115012_bb0440","doi-asserted-by":"crossref","first-page":"9","DOI":"10.21037\/atm-22-3027","article-title":"The m6A methyltransferase WTAP plays a key role in the development of diffuse large B-cell lymphoma via regulating the m6A modification of catenin beta 1","volume":"10","author":"Guo","year":"2022","journal-title":"Annals of Translational Medicine"},{"key":"10.1016\/j.intimp.2025.115012_bb0445","first-page":"281","volume":"116","author":"Bartel","year":"2004","journal-title":"MicroRNAs: genomics, biogenesis, mechanism, and function, cell"},{"key":"10.1016\/j.intimp.2025.115012_bb0450","doi-asserted-by":"crossref","first-page":"396","DOI":"10.1038\/s41580-023-00694-9","article-title":"Transcription regulation by long non-coding RNAs: mechanisms and disease relevance","volume":"25","author":"Ferrer","year":"2024","journal-title":"Nat. Rev. Mol. Cell Biol."},{"key":"10.1016\/j.intimp.2025.115012_bb0455","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1186\/s12943-019-0977-3","article-title":"MiR155 sensitized B-lymphoma cells to anti-PD-L1 antibody via PD-1\/PD-L1-mediated lymphoma cell interaction with CD8+ T cells","volume":"18","author":"Zheng","year":"2019","journal-title":"Mol. Cancer"},{"key":"10.1016\/j.intimp.2025.115012_bb0460","doi-asserted-by":"crossref","first-page":"15035","DOI":"10.18632\/oncotarget.3729","article-title":"MicroRNA-21 plays an oncogenic role by targeting FOXO1 and activating the PI3K\/AKT pathway in diffuse large B-cell lymphoma","volume":"6","author":"Go","year":"2015","journal-title":"Oncotarget"},{"key":"10.1016\/j.intimp.2025.115012_bb0465","doi-asserted-by":"crossref","first-page":"18077","DOI":"10.3390\/ijms160818077","article-title":"MiR-199a And miR-497 Are Associated with Better Overall Survival Due to Increased Chemosensitivity in Aggressive Non-Hodgkin \u0301s Lymphoma Patients","volume":"16","author":"Troppan","year":"2015","journal-title":"J. Mol. Sci."},{"key":"10.1016\/j.intimp.2025.115012_bb0470","article-title":"A 9-LncRNA signature for predicting prognosis and immune response in diffuse large B-cell lymphoma","volume":"13","author":"Wang","year":"2022","journal-title":"Front. Immunol."},{"key":"10.1016\/j.intimp.2025.115012_bb0475","doi-asserted-by":"crossref","first-page":"731","DOI":"10.1038\/s41419-019-1886-5","article-title":"LncRNA SNHG14\/miR-5590-3p\/ZEB1 positive feedback loop promoted diffuse large B cell lymphoma progression and immune evasion through regulating PD-1\/PD-L1 checkpoint","volume":"10","author":"Zhao","year":"2019","journal-title":"Cell Death Dis."},{"key":"10.1016\/j.intimp.2025.115012_bb0480","doi-asserted-by":"crossref","DOI":"10.1016\/j.lfs.2019.03.040","article-title":"LncRNA MALAT1 promotes tumorigenesis and immune escape of diffuse large B cell lymphoma by sponging miR-195","volume":"231","author":"Wang","year":"2019","journal-title":"Life Sci."},{"key":"10.1016\/j.intimp.2025.115012_bb0485","first-page":"CD-19-0116","article-title":"Selective inhibition of HDAC3 targets synthetic vulnerabilities and activates immune surveillance in lymphoma, Cancer","volume":"10","author":"Mondello","year":"2020","journal-title":"Discovery"},{"key":"10.1016\/j.intimp.2025.115012_bb0490","doi-asserted-by":"crossref","first-page":"440","DOI":"10.1158\/2159-8290.CD-19-0116","article-title":"Selective inhibition of HDAC3 targets synthetic vulnerabilities and activates immune surveillance in lymphoma","volume":"10","author":"Mondello","year":"2020","journal-title":"Cancer Discov."},{"key":"10.1016\/j.intimp.2025.115012_bb0495","doi-asserted-by":"crossref","first-page":"535","DOI":"10.1016\/j.immuni.2019.08.006","article-title":"Unique and shared epigenetic programs of the CREBBP and EP300 acetyltransferases in germinal center B cells reveal targetable dependencies in lymphoma","volume":"51","author":"Meyer","year":"2019","journal-title":"Immunity"},{"key":"10.1016\/j.intimp.2025.115012_bb0500","first-page":"1","article-title":"Finding an easy way to harmonize: a review of advances in clinical research and combination strategies of EZH2 inhibitors, clinical","volume":"13","author":"Li","year":"2021","journal-title":"Epigenetics"},{"key":"10.1016\/j.intimp.2025.115012_bb0505","doi-asserted-by":"crossref","first-page":"513","DOI":"10.1007\/s40265-020-01288-x","article-title":"Tazemetostat: first approval","volume":"80","author":"Hoy","year":"2020","journal-title":"Drugs"},{"key":"10.1016\/j.intimp.2025.115012_bb0510","doi-asserted-by":"crossref","first-page":"1123","DOI":"10.1111\/cas.14822","article-title":"Phase 1 study of tazemetostat in Japanese patients with relapsed or refractory B-cell lymphoma","volume":"112","author":"Munakata","year":"2021","journal-title":"Cancer Sci."},{"key":"10.1016\/j.intimp.2025.115012_bb0515","doi-asserted-by":"crossref","first-page":"853","DOI":"10.1182\/blood-2023-174607","article-title":"Results of the phase II of Epirchop study, evaluating the efficacy of Tazemetostat in combination with R-CHOP in elderly newly diagnosed diffuse large B cell lymphoma (DLBCL): a Lysa study","volume":"142","author":"Sarkozy","year":"2023","journal-title":"Blood"},{"key":"10.1016\/j.intimp.2025.115012_bb0520","doi-asserted-by":"crossref","first-page":"49","DOI":"10.1016\/j.ccell.2024.11.006","article-title":"EZH2 inhibition enhances T cell immunotherapies by inducing lymphoma immunogenicity and improving T cell function","volume":"43","author":"Isshiki","year":"2025","journal-title":"Cancer Cell"},{"key":"10.1016\/j.intimp.2025.115012_bb0525","doi-asserted-by":"crossref","first-page":"5226","DOI":"10.1182\/bloodadvances.2020002580","article-title":"Combined EZH2 and Bcl-2 inhibitors as precision therapy for genetically defined DLBCL subtypes","volume":"4","author":"Scholze","year":"2020","journal-title":"Blood Adv."},{"key":"10.1016\/j.intimp.2025.115012_bb0530","doi-asserted-by":"crossref","first-page":"5401","DOI":"10.1158\/1078-0432.CCR-20-4027","article-title":"Combined EZH2 inhibition and IKAROS degradation leads to enhanced antitumor activity in diffuse large B-cell lymphoma","volume":"27","author":"Tong","year":"2021","journal-title":"Clin. Cancer Res."},{"key":"10.1016\/j.intimp.2025.115012_bb0535","doi-asserted-by":"crossref","first-page":"2541","DOI":"10.3390\/cancers12092541","article-title":"Combination treatment with GSK126 and pomalidomide induces B-cell differentiation in EZH2 gain-of-function mutant diffuse large B-cell lymphoma","volume":"12","author":"Park","year":"2020","journal-title":"Cancers"},{"key":"10.1016\/j.intimp.2025.115012_bb0540","doi-asserted-by":"crossref","DOI":"10.3389\/fgene.2021.742561","article-title":"Emerging advances in combinatorial treatments of epigenetically altered pediatric high-grade H3K27M gliomas","volume":"12","author":"Leszczynska","year":"2021","journal-title":"Front. Genet."},{"key":"10.1016\/j.intimp.2025.115012_bb0545","doi-asserted-by":"crossref","first-page":"1247","DOI":"10.1634\/theoncologist.12-10-1247","article-title":"FDA approval summary: vorinostat for treatment of advanced primary cutaneous T-cell lymphoma","volume":"12","author":"Mann","year":"2007","journal-title":"Oncologist"},{"key":"10.1016\/j.intimp.2025.115012_bb0550","doi-asserted-by":"crossref","first-page":"997","DOI":"10.1586\/era.10.88","article-title":"Romidepsin: a new therapy for cutaneous T-cell lymphoma and a potential therapy for solid tumors","volume":"10","author":"Grant","year":"2010","journal-title":"Expert. Rev. Anticancer. Ther."},{"key":"10.1016\/j.intimp.2025.115012_bb0555","doi-asserted-by":"crossref","first-page":"202","DOI":"10.1177\/2040620715592567","article-title":"Belinostat in patients with refractory or relapsed peripheral T-cell lymphoma: a perspective review","volume":"6","author":"Sawas","year":"2015","journal-title":"Therapeutic advances in hematology"},{"key":"10.1016\/j.intimp.2025.115012_bb0560","doi-asserted-by":"crossref","first-page":"1195","DOI":"10.1016\/S1470-2045(14)70440-1","article-title":"Panobinostat plus bortezomib and dexamethasone versus placebo plus bortezomib and dexamethasone in patients with relapsed or relapsed and refractory multiple myeloma: a multicentre, randomised, double-blind phase 3 trial","volume":"15","author":"San-Miguel","year":"2014","journal-title":"Lancet Oncol."},{"key":"10.1016\/j.intimp.2025.115012_bb0565","doi-asserted-by":"crossref","first-page":"964","DOI":"10.1093\/annonc\/mdn031","article-title":"Phase II trial of oral vorinostat (suberoylanilide hydroxamic acid) in relapsed diffuse large-B-cell lymphoma","volume":"19","author":"Crump","year":"2008","journal-title":"Ann. Oncol."},{"key":"10.1016\/j.intimp.2025.115012_bb0570","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1186\/s13148-016-0245-y","article-title":"Combinatorial epigenetic therapy in diffuse large B cell lymphoma pre-clinical models and patients","volume":"8","author":"Pera","year":"2016","journal-title":"Clin. Epigenetics."},{"key":"10.1016\/j.intimp.2025.115012_bb0575","doi-asserted-by":"crossref","first-page":"692","DOI":"10.3109\/10428194.2015.1063143","article-title":"Anti-tumor activity of the combination of bendamustine with vorinostat in diffuse large B-cell lymphoma cells","volume":"57","author":"Fern\u00e1ndez-Rodr\u00edguez","year":"2016","journal-title":"Leuk. Lymphoma"},{"key":"10.1016\/j.intimp.2025.115012_bb0580","article-title":"Case report: dual inhibition of HDAC and BTK for diffuse large b-cell lymphoma after failure to CD19-targeted CAR-T therapy","volume":"13","author":"Zhu","year":"2022","journal-title":"Front. Immunol."},{"key":"10.1016\/j.intimp.2025.115012_bb0585","doi-asserted-by":"crossref","first-page":"903","DOI":"10.3324\/haematol.2016.154377","article-title":"Safety and efficacy of abexinostat, a pan-histone deacetylase inhibitor, in non-Hodgkin lymphoma and chronic lymphocytic leukemia: results of a phase II study","volume":"102","author":"Ribrag","year":"2017","journal-title":"Haematologica"},{"key":"10.1016\/j.intimp.2025.115012_bb0590","first-page":"185","article-title":"Phase 2 study of panobinostat with or without rituximab in relapsed diffuse large B-cell lymphoma, blood, the journal of the American society of","volume":"128","author":"Assouline","year":"2016","journal-title":"Hematology"},{"key":"10.1016\/j.intimp.2025.115012_bb0595","first-page":"721","article-title":"Pharmacodynamic response and inhibition of growth of human tumor xenografts by the novel histone deacetylase inhibitor PXD101","volume":"2","author":"Plumb","year":"2003","journal-title":"Mol. Cancer Ther."},{"key":"10.1016\/j.intimp.2025.115012_bb0600","doi-asserted-by":"crossref","first-page":"2359","DOI":"10.3109\/10428194.2015.1135431","article-title":"A phase II study of belinostat (PXD101) in relapsed and refractory aggressive B-cell lymphomas: SWOG S0520","volume":"57","author":"Puvvada","year":"2016","journal-title":"Leuk. Lymphoma"},{"key":"10.1016\/j.intimp.2025.115012_bb0605","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1186\/s13045-017-0439-6","article-title":"Chidamide in relapsed or refractory peripheral T cell lymphoma: a multicenter real-world study in China","volume":"10","author":"Shi","year":"2017","journal-title":"J. Hematol. Oncol."},{"key":"10.1016\/j.intimp.2025.115012_bb0610","first-page":"1","article-title":"Chidamide enhances T-cell-mediated anti-tumor immune function by inhibiting NOTCH1\/NFATC1 signaling pathway in ABC-type diffuse large B-cell lymphoma","author":"Li","year":"2024","journal-title":"Leuk. Lymphoma"},{"key":"10.1016\/j.intimp.2025.115012_bb0615","first-page":"1","article-title":"Clinical efficacy and molecular biomarkers in a phase II study of tucidinostat plus R-CHOP in elderly patients with newly diagnosed diffuse large B-cell lymphoma, clinical","volume":"12","author":"Zhang","year":"2020","journal-title":"Epigenetics"},{"key":"10.1016\/j.intimp.2025.115012_bb0620","doi-asserted-by":"crossref","DOI":"10.3389\/fphar.2022.932914","article-title":"Therapeutic potential of tucidinostat, a subtype-selective HDAC inhibitor, in cancer treatment","volume":"13","author":"Sun","year":"2022","journal-title":"Front. Pharmacol."},{"key":"10.1016\/j.intimp.2025.115012_bb0625","doi-asserted-by":"crossref","first-page":"1017","DOI":"10.1080\/13543776.2016.1209488","article-title":"DNA methyltransferase inhibitors: an updated patent review (2012-2015)","volume":"26","author":"Xu","year":"2016","journal-title":"Expert Opin. Ther. Pat."},{"key":"10.1016\/j.intimp.2025.115012_bb0630","doi-asserted-by":"crossref","first-page":"1404","DOI":"10.1634\/theoncologist.2015-0165","article-title":"Oral azacitidine (CC-486) for the treatment of myelodysplastic syndromes and acute myeloid leukemia","volume":"20","author":"Cogle","year":"2015","journal-title":"Oncologist"},{"key":"10.1016\/j.intimp.2025.115012_bb0635","doi-asserted-by":"crossref","first-page":"S453","DOI":"10.1016\/S2152-2650(24)01476-9","article-title":"ABCL-006 Azacytidine plus rituximab\u2013gemcitabine\u2013oxaliplatin as salvage treatment in patients with relapsed\/refractory diffuse large B-cell lymphoma","volume":"24","author":"Fanqiao","year":"2024","journal-title":"Clin. Lymphoma Myeloma Leuk."},{"key":"10.1016\/j.intimp.2025.115012_bb0640","doi-asserted-by":"crossref","DOI":"10.1371\/journal.pone.0009001","article-title":"A comparison of azacitidine and decitabine activities in acute myeloid leukemia cell lines","volume":"5","author":"Hollenbach","year":"2010","journal-title":"PLoS One"},{"key":"10.1016\/j.intimp.2025.115012_bb0645","first-page":"5506","article-title":"HDAC inhibitors and decitabine are highly synergistic and associated with unique gene-expression and epigenetic profiles in models of DLBCL, blood, the journal of the American society of","volume":"118","author":"Kalac","year":"2011","journal-title":"Hematology"},{"key":"10.1016\/j.intimp.2025.115012_bb0650","doi-asserted-by":"crossref","first-page":"8134","DOI":"10.1002\/cam4.5615","article-title":"Decitabine combined with RDHAP regimen in relapsed\/refractory diffuse large B cell lymphoma","volume":"12","author":"Kong","year":"2023","journal-title":"Cancer Med."},{"key":"10.1016\/j.intimp.2025.115012_bb0655","article-title":"Combination of decitabine and a modified regimen of cisplatin, cytarabine and dexamethasone: a potential salvage regimen for relapsed or refractory diffuse large B-cell lymphoma after second-line treatment failure","volume":"11","author":"Hu","year":"2021","journal-title":"Front. Oncol."},{"key":"10.1016\/j.intimp.2025.115012_bb0660","doi-asserted-by":"crossref","DOI":"10.3389\/fimmu.2022.969660","article-title":"Decitabine-primed tandem CD19\/CD22 CAR-T therapy in relapsed\/refractory diffuse large B-cell lymphoma patients","volume":"13","author":"Qu","year":"2022","journal-title":"Front. Immunol."}],"container-title":["International Immunopharmacology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1567576925010021?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1567576925010021?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2026,4,9]],"date-time":"2026-04-09T19:48:39Z","timestamp":1775764119000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S1567576925010021"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,8]]},"references-count":132,"alternative-id":["S1567576925010021"],"URL":"https:\/\/doi.org\/10.1016\/j.intimp.2025.115012","relation":{},"ISSN":["1567-5769"],"issn-type":[{"value":"1567-5769","type":"print"}],"subject":[],"published":{"date-parts":[[2025,8]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Targeting epigenetic reprogramming in DLBCL and its interaction with the tumor microenvironment for novel therapeutic approaches","name":"articletitle","label":"Article Title"},{"value":"International Immunopharmacology","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.intimp.2025.115012","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2025 Elsevier B.V. All rights are reserved, including those for text and data mining, AI training, and similar technologies.","name":"copyright","label":"Copyright"}],"article-number":"115012"}}